Sign In  |  Register  |  About Burlingame  |  Contact Us

Burlingame, CA
September 01, 2020 10:18am
7-Day Forecast | Traffic

  • Search Hotels in Burlingame

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Astellas Pharma Inc (OP: ALPMY )

15.29 -0.03 (-0.16%)
Streaming Delayed Price Updated: 3:52 PM EDT, May 20, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 43,708
Open 15.24
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 15.31
Today's Range 15.19 - 15.32
52wk Range 14.21 - 18.46
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Twist Bioscience, Astellas Join Forces To Develop Cancer Targeting Antibodies
 
Via Benzinga
Astellas - Seagen's Padcev Approved In Europe For Most Common Form Of Bladder Cancer
The  
Via Benzinga

Performance

YTD
-6.05%
-6.05%
1 Month
-4.59%
-4.59%
3 Month
-12.56%
-12.56%
6 Month
-10.30%
-10.30%
1 Year
-1.51%
-1.51%

More News

Read More
Astellas' Menopause Drug Suffers Setback After Failed Asian Trial
Via Benzinga
Astellas Touts Safety Data For Phase 3 Menopause Drug, Sets Up US Filing
Via Benzinga
Astellas Pharma - Seagen's Enfortumab Shows 36% Pathologic Complete Response In Bladder Cancer Patients
Via Benzinga
Gene Therapy-Focused Dyno Therapeutics Adds Astellas To List Partner List With $1.6B Pact
Via Benzinga
4 No-Brainer Pharmaceutical Stocks to Buy in October
Via Talk Markets
Exposures COVID-19
Astellas Pharma's Bladder Cancer Treatment Scores Approval In Japan
Via Benzinga
The Daily Biotech Pulse: NRx Rises On COVID-19 Drug Collaboration, Amgen's Lung Cancer Drug Conditionally Approved In Canada, Coherus Data Readout
Via Benzinga
Exposures COVID-19
Astellas' Gene Therapy Trial Hit With Another Death, FDA Slaps Clinical Hold
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: Merck Releases Twin Dose Of Positive Tidings, Astellas Voluntarily Pauses Gene Therapy Study, Ascendis Offering
Via Benzinga
See Why Astellas Stopped Dosing In Neuromuscular Disease Gene Therapy Trial
Via Benzinga
After FDA Rejection, EMA Approves FibroGen-Astellas' Roxadustat
Via Benzinga
Exposures Product Safety
Here's What Recent News From the FDA Means for AstraZeneca
Via The Motley Fool
Exposures Product Safety
FibroGen Shares Are Trading Lower As FDA Shoots Down Roxadustat Application, Asks For Additional Trial
Via Benzinga
Exposures Product Safety
The IPO Recap – Party Is Everything But Over
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data
Via Benzinga
Exposures COVID-19
Astellas - Seagen's PADCEV Wins Full FDA Approval And Expanded Label In Tough-To-Treat Urothelial Cancer
Via Benzinga
Exposures Product Safety
The 2 Best Pharma Stocks to Buy on Dips
Via Talk Markets
Exposures COVID-19
Adaptimmune's HiT Program Can Potentially Kill Human Tumor Cells, Animal Study Shows
Via Benzinga
Astellas Walks Away From $450M Research & Discovery Partnership With Cytokinetics
Via Benzinga
Topics Regulatory Compliance
Exposures Legal Regulatory
Astellas Takes $540M Impairment Charge Of $3B Audentes Buy­out On Gene Therapy Trial Hold
Via Benzinga
FibroGen Stock Is Trading Lower As CEO Admits Manipulated Safety Data For Roxadustat
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Burlingame.com & California Media Partners, LLC. All rights reserved.